MSF's Suerie Moon spoke in front of a US Senate Committee on promoting new treatments & cures for neglected diseases read more
NEW: The 13th Edition of Untangling the Web of Antiretroviral Price Reductions is now available download it here
VIDEO: MSF's community approach to treating malnutrition in Niger watch it here
WHO's work on the financing of medical research and development is given a fresh start read more
MSF Letter to GFATM on concerns over scale-up of AIDS treatment in light of Board of Directors Meeting read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
|
 |
|
 |
Company: Sequoia Pharmaceuticals, Inc.
Headquarters: Gaithersburg, USA
We want Sequoia Pharmaceuticals to put these drug patents in the pool:
SPI-452
Currently in clinical trials
SPI-452 is a new class of booster drug that when given with some antiretrovirals, increases their drug levels in the blood to make them more effective. This drug is still at the early stages of development but it would be important to get the patents in the pool - at the moment, there is only one other booster available, and it’s important to have more options.
FATAL FLAWS: How Kenya's 2008 Anti-Counterfeit Act could endanger access to medicines 
Presenation: Missing ARVs for HIV/AIDS treatment in 2009 - Unitaid Patent Pool Briefing
HIV/AIDS treatment in developing countries: the battle for long-term survival has just begun
